Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
An aminoglycoside is a type of antibiotic used mainly for serious infections caused by susceptible bacteria. These medicines interfere with bacterial protein production and have a rapid bactericidal effect. Examples include gentamicin, tobramycin, amikacin, streptomycin, neomycin, and plazomicin. Their use is limited by the risk of kidney damage, hearing loss, and other serious adverse effects.
read more about aminoglycoside ...Aminoglycosides are used for selected severe infections caused primarily by aerobic gram-negative bacteria. They can be prescribed for bloodstream infections, complicated urinary infections, abdominal infections, and infections involving resistant organisms. Certain aminoglycosides are used for tuberculosis, plague, tularemia, or specific parasitic infections. They are sometimes combined with another antibiotic to broaden coverage or improve activity against selected bacteria.
Aminoglycosides enter susceptible bacteria and bind mainly to the 30S portion of the bacterial ribosome. This disrupts the reading of genetic instructions and causes the production of abnormal proteins. The resulting damage interferes with the bacterial cell membrane and leads to cell death. Bacteria can become resistant through drug-modifying enzymes, changes to the ribosomal target, reduced entry, or increased drug removal.
Systemic aminoglycosides are usually given through a vein or into a muscle because most are poorly absorbed from the digestive tract. Some formulations are used in the eyes, ears, lungs, skin, or intestine for specific purposes. Clinicians adjust the dose according to body weight, kidney function, infection severity, and the medicine being used. Blood drug levels, kidney tests, fluid status, and hearing or balance symptoms can require monitoring during treatment.
The main serious risks are nephrotoxicity, ototoxicity, and neuromuscular blockade. Kidney injury is often detected through changes in creatinine or urine output, while ear damage can cause hearing loss, ringing in the ears, dizziness, or balance problems. Risk increases with prolonged treatment, high exposure, kidney impairment, older age, dehydration, or other medicines that affect the kidneys or ears. Patients should promptly report reduced urination, hearing changes, severe weakness, or breathing difficulty.
Aminoglycosides act against many aerobic gram-negative bacteria and selected gram-positive bacteria, but they do not cover every organism. Their usefulness depends on the specific drug, infection, resistance pattern, and whether another antibiotic is given with them.
Most aminoglycosides are poorly absorbed through the gastrointestinal tract, so oral doses do not produce reliable blood levels for systemic infections. Oral or locally delivered forms are still used for certain targeted purposes.
Yes. Aminoglycoside-related hearing or balance damage can be permanent, although the risk differs among drugs and patients. New hearing changes, tinnitus, dizziness, or imbalance should be reported promptly.
Aminoglycosides generally have little activity against anaerobic bacteria because bacterial uptake of the drug depends on an oxygen-related transport process. Another antibiotic is usually needed when anaerobic coverage is required.
Aminoglycosides. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK541105/. Date Accessed August 5, 2026.
Aminoglycosides: An Overview. Cold Spring Harbor Perspectives in Medicine (PubMed Central). https://pmc.ncbi.nlm.nih.gov/articles/PMC4888811/. Date Accessed August 5, 2026.
Gentamicin. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK557550/. Date Accessed August 5, 2026.
Tobramycin. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK551695/. Date Accessed August 5, 2026.
Aminoglycosides-Related Ototoxicity: Mechanisms, Risk Factors, and Prevention in Pediatric Patients. PubMed Central. https://pmc.ncbi.nlm.nih.gov/articles/PMC10610175/. Date Accessed August 5, 2026.